Intravenous and subcutaneous immunoglobulin G replacement therapy

Area of Science:

• Immunology
• Pharmacology
• Therapeutics

Background:

• Human polyclonal immunoglobulin G (IgG) has a long history in therapeutic antibody deficiency treatment.
• Its applications have expanded to anti-inflammatory and immunomodulatory uses.
• This review concentrates on IgG for replacement therapy.

Purpose of the Study:

• To review and compare the prescribing of IgG for replacement therapy.
• To analyze the pharmacokinetics and adverse effects of different IgG administration routes.
• To emphasize the importance of individualized therapy selection.

Main Methods:

• Review of existing literature on IgG therapy, focusing on intravenous IgG (IVIG), subcutaneous IgG (SCIG), and hyaluronidase-facilitated SCIG.
• Comparison of administration routes, dosing frequencies, pharmacokinetics, bioavailability, and adverse event profiles.
• Discussion of factors necessitating individualized treatment plans.

Main Results:

• IVIG exhibits high peak and low trough IgG concentrations; SCIG shows less fluctuation.
• Hyaluronidase-facilitated SCIG offers intermediate pharmacokinetics and potentially better bioavailability than standard SCIG.
• Adverse effects vary, with IVIG associated with systemic flu-like symptoms and SCIG with local site reactions; thrombotic and renal events are rare but serious risks.

Conclusions:

• Optimal IgG replacement therapy requires careful consideration of administration route (IVIG, SCIG, hyaluronidase-SCIG), pharmacokinetics, and individual patient factors.
• Individualization of IgG therapy is essential due to variations in IgG half-life and product differences.
• A variety of IgG products and administration methods allow for tailored patient treatment.